Giganteone A and malabaricone C as potential pharmacotherapy for diabetes mellitus

Sivasothy, Yasodha and Leong, Kok Hoong and Loo, Kong Yong and Wahab, Siti Mariam Adbul and Othman, Muhamad Aqmal and Awang, Khalijah (2022) Giganteone A and malabaricone C as potential pharmacotherapy for diabetes mellitus. Natural Product Research, 36 (6). pp. 1581-1586. ISSN 1478-6419, DOI

Full text not available from this repository.


The use of antidiabetic agents which control glycemic levels in the blood and simultaneously inhibit oxidative stress is an important strategy in the prevention of Diabetes Mellitus and its complications. In our previous study, malabaricone C (3) and its dimer, giganteone A (5) exhibited significant DPPH free radical scavenging activities which were lower than the activity of the positive control, ascorbic acid. These compounds were evaluated for their alpha-glucosidase inhibitory activities at different concentrations (0.02-2.5 mM) in the present study. Compounds 3 (IC50 59.61 mu M) and 5 (IC50 39.52 mu M) were identified as active alpha-glucosidase inhibitors, each respectively being 24 and 37 folds more potent than the standard inhibitor, acarbose. Based on the molecular docking studies, compounds 3 and 5 docked into the active site of the alpha-glucosidase enzyme, forming mainly hydrogen bonds in the active site.

Item Type: Article
Funders: Ministry of Education, Malaysia [Grant No: FP002-2018A], Universiti Malaya [Grant No: RP001-2012 & BK002-2015]
Uncontrolled Keywords: Myristica cinnamomea King; Giganteone A; Malabaricone C; Malabaricone E; α -glucosidase inhibitory activity
Subjects: Q Science > QD Chemistry
R Medicine > RS Pharmacy and materia medica
Divisions: Faculty of Science
Faculty of Pharmacy
Depositing User: Ms. Juhaida Abd Rahim
Date Deposited: 22 Apr 2022 08:16
Last Modified: 22 Apr 2022 08:16

Actions (login required)

View Item View Item